BioCentury | Sep 20, 2010
Company News

Draxis, Eli Lilly Canada Inc. sales and marketing update

...Lilly $6 million over five years plus additional payments that vary depending on market conditions. Draxis Health Inc....
BioCentury | Jun 2, 2008
Company News

Draxis, Jubilant Organosys deal

...Draxis for US$6 per share, or about US$255 million in cash (see BioCentury, April 14). Draxis Health Inc....
BioCentury | Apr 14, 2008
Company News

Draxis, Jubilant Organosys deal

...Jubilant Organosys, an Indian CRO, will acquire radiopharmaceutical and manufacturing services company Draxis for US$6 per...
...in cash. Lazard Ltd. advised Jubilant Organosys, and Banc of America Securities Canada Co. advised Draxis...
...Dec. 31, 2007, Draxis had US$24.8 million in cash and 12-month sales of US$76.1 million. Draxis Health Inc....
BioCentury | Jan 14, 2008
Company News

Draxis management update

...president and CEO from COO; and Jean-Pierre Robert to COO while remaining president of Draxis' Draxis...
BioCentury | Aug 27, 2007
Company News

Draxis, Med Discovery S.A. deal

...Draximage will be responsible for radiolabeling and preclinical testing. The companies will share resulting IP. Draxis Health Inc....
BioCentury | Jul 30, 2007
Company News

Draxis management update

...president of DAX's Draxis Specialty Pharmaceuticals Inc. subsidiary from president of Draximage, a unit of Draxis...
BioCentury | May 21, 2007
Finance

NASDAQ additions

...up and four were down on the week. The update saw the return of of Draxis...
...AKRX) $6.77 -3% Alexza (ALXA) $10.07 1% BioMimetic (BMTI) $18.15 0% CombinatoRx (CRXX) $6.48 -7% Draxis...
BioCentury | Nov 20, 2006
Finance

NASDAQ additions

...one company was removed from the index this time - drug delivery and radiopharmaceutical company Draxis...
BioCentury | Apr 3, 2006
Clinical News

Fibrimage: Development discontinued

...Fibrimage met the primary endpoint in Canadian Phase III trial (see BioCentury, May 9, 2005). Draxis Health Inc....
BioCentury | May 23, 2005
Finance

NASDAQ Biotech additions

...Wk chg Prior wk Barrier (BTRX) $18.34 4% 0% Cardiome (CRME; TSE:COM) $5.57 -6% -9% Draxis...
Items per page:
1 - 10 of 136
BioCentury | Sep 20, 2010
Company News

Draxis, Eli Lilly Canada Inc. sales and marketing update

...Lilly $6 million over five years plus additional payments that vary depending on market conditions. Draxis Health Inc....
BioCentury | Jun 2, 2008
Company News

Draxis, Jubilant Organosys deal

...Draxis for US$6 per share, or about US$255 million in cash (see BioCentury, April 14). Draxis Health Inc....
BioCentury | Apr 14, 2008
Company News

Draxis, Jubilant Organosys deal

...Jubilant Organosys, an Indian CRO, will acquire radiopharmaceutical and manufacturing services company Draxis for US$6 per...
...in cash. Lazard Ltd. advised Jubilant Organosys, and Banc of America Securities Canada Co. advised Draxis...
...Dec. 31, 2007, Draxis had US$24.8 million in cash and 12-month sales of US$76.1 million. Draxis Health Inc....
BioCentury | Jan 14, 2008
Company News

Draxis management update

...president and CEO from COO; and Jean-Pierre Robert to COO while remaining president of Draxis' Draxis...
BioCentury | Aug 27, 2007
Company News

Draxis, Med Discovery S.A. deal

...Draximage will be responsible for radiolabeling and preclinical testing. The companies will share resulting IP. Draxis Health Inc....
BioCentury | Jul 30, 2007
Company News

Draxis management update

...president of DAX's Draxis Specialty Pharmaceuticals Inc. subsidiary from president of Draximage, a unit of Draxis...
BioCentury | May 21, 2007
Finance

NASDAQ additions

...up and four were down on the week. The update saw the return of of Draxis...
...AKRX) $6.77 -3% Alexza (ALXA) $10.07 1% BioMimetic (BMTI) $18.15 0% CombinatoRx (CRXX) $6.48 -7% Draxis...
BioCentury | Nov 20, 2006
Finance

NASDAQ additions

...one company was removed from the index this time - drug delivery and radiopharmaceutical company Draxis...
BioCentury | Apr 3, 2006
Clinical News

Fibrimage: Development discontinued

...Fibrimage met the primary endpoint in Canadian Phase III trial (see BioCentury, May 9, 2005). Draxis Health Inc....
BioCentury | May 23, 2005
Finance

NASDAQ Biotech additions

...Wk chg Prior wk Barrier (BTRX) $18.34 4% 0% Cardiome (CRME; TSE:COM) $5.57 -6% -9% Draxis...
Items per page:
1 - 10 of 136